[November 27, 2015]

Research and Markets: OpportunityAnalyzer: Growth Hormone Deficiency Study 2015 - Opportunity Analysis and Forecast to 2024

Research and Markets has announced the addition of the "OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecast to 2024" report to their offering.

OpportunityAnalyzer: Growth Hormone Deficiency - Opportunity Analysis and Forecast to 2024 estimates the 2014 sales for growth hormone deficiency (GHD) at approximately $1.26 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 4.08% during the 10-year forecast period, generating sales of approximately $1.88 billion at the end of 2024.

The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.88% and generating around 59% of global sales in 2024. The major driver for this growth across the 7MM will be the launch of long-acting biobetter growth hormones (GH), which will rapidly take away shares from the currently marketed daily injectable growth hormones.

Key Questions Answered

• Overall, the greatest unmet need in the GHD space is the issue with treatment adherece and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
• The 10-year forecast period will mark the launch of six pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
• What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands, especially in the US? What are the chances of reimbursement for the long-acting GH drugs in pipeline?

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Competitive Assessment

6 Unmet Needs Assessment and Opportunity Analysis

7 R&D Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

Companies Mentioned

• Ipsen SA
• Pfizer
• Genentech/Roche
• Novo Nordisk
• Eli Lilly
• Sandoz
• EMD Serono
• Ferring
• JCR Pharmaceuticals
• Teva
• LG Life Sciences
• Biopartners GmbH
• Versartis Inc.
• Ascendis Pharma
• Genexine Inc.
• Hanmi Pharmaceuticals
• Aileron Therapeutics
• Critical Pharmaceuticals Limited
• Emisphere Technologies Inc.
• Alteogen Inc.

For more information visit http://www.researchandmarkets.com/research/rmxf8p/opportunityanalyze

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005291/en/

[ Back To TMCnet.com's Homepage ]